13:07 EST Novo Nordisk (NVO) down 4% to $46.59 after detailing sales hit from weight loss pact
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Trump says GLP-1 drugs to be available directly to consumer at TrumpRx website
- Trump announces deals with Lilly, Novo Nordisk to lower obesity drug prices
- Novo Nordisk, Eli Lilly to cut GLP-1 prices, Trump says
- Trump says Americans should pay lowest global prices for drugs
- Trump says other countries ‘not happy’ with drug pricing deals